Figure 3: Immunohistochemical studies of hepatic plasminogen activator inhibitor-1 (PAI-1) levels. | Scientific Reports

Figure 3: Immunohistochemical studies of hepatic plasminogen activator inhibitor-1 (PAI-1) levels.

From: Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance

Figure 3

Representative livers from a chronic hepatitis C (CHC) patient with severe fibrosis and some inflammation (A, 100X; B, 200X) and another CHC patient with severe inflammation, steatosis and mild fibrosis (C, 100X; D, 200X) before the initiation of anti-hepatitis C virus therapy. A liver specimen from a normal subject was stained for PAI-1 (E, 100X; F, 200X) and served as a negative control (without HCV infection). A hepatocellular carcinoma specimen served as a positive control for PAI-1 staining (G, 100X; H, 200X). The arrows indicate PAI-1-positive stained cells. Black arrows: biliary and endothelial cells; red arrows: malignant hepatocytes.

Back to article page